Keywords (1)

Academic
Publications
Outcome of Deferred Initial Therapy in Mantle-Cell Lymphoma

Outcome of Deferred Initial Therapy in Mantle-Cell Lymphoma,10.1200/JCO.2008.19.6121,Journal of Clinical Oncology,P. Martin,A. Chadburn,P. Christos,K.

Outcome of Deferred Initial Therapy in Mantle-Cell Lymphoma   (Citations: 21)
BibTex | RIS | RefWorks Download
P. Martin, A. Chadburn, P. Christos, K. Weil, R. R. Furman, J. Ruan, R. Elstrom, R. Niesvizky, S. Ely, M. DiLiberto, A. Melnick, D. M. Knowleshttp://academic.research.microsoft.com/io.ashx?type=5&id=30826388&selfId1=0&selfId2=0&maxNumber=12&query=
Journal: Journal of Clinical Oncology - J CLIN ONCOL , vol. 27, no. 8, pp. 1209-1213, 2009
Cumulative Annual
View Publication
The following links allow you to view full publications. These links are maintained by other sources not affiliated with Microsoft Academic Search.
    • ... For rare individuals with a phenotype and cytogenetic studies suggestive of mantle cell lymphoma or another aggressive NHL subtype but without adenopathy on computed tomography scanning or substantial marrow involvement on marrow biopsy, we suggest clinical follow-up every 3–6 months with computed tomography imaging at least every 6 months...

    T D Shanafeltet al. Monoclonal B-cell lymphocytosis (MBL): biology, natural history and cl...

    • ...Another likely explanation may be that both melanoma and LPDs are common cancers and their association may simply represent the improvement in diagnostic modalities and cancer reporting. Any of these reasons except treatment could have been responsible for the concurrent cancers in our patient.The identification of synchronous cancers may present difficulties in terms of management decisions and prognosis. The standard management for stage A CLL is a conservative watch and wait approach. It is currently believed that asymptomatic MCL patients do not benefit from early interventions and are best monitored closely [...

    Juanah Addadaet al. Synchronous Mantle Cell Lymphoma, Chronic Lymphocytic Leukaemia and Me...

    • ...Recent developments, however, suggest that MCL may have a more heterogeneic disease course, ranging from highly aggressive disease requiring upfront intensive treatment, including autologous stem cell transplantation (ASCT), to smoldering disease, for which even deferred treatment might be appropriate [2]...
    • ...The development of more powerful prognostic assessment, together with follow-up data from an increasing number of MCL patient cohorts, provides better tools for choosing therapy ranging from palliative treatment to high-dose therapy with curative intent, but now also including the option of deferring therapy in asymptomatic patients [2]...

    Christian Geisler. Mantle cell lymphoma: Are current therapies changing the course of dis...

Sort by: